



# Q2/1H 2024

Second quarter and half year results  
Navamedic ASA



## Contents

Highlights for the first half year 2024 .....	3
Key figures .....	3
Comment from the CEO .....	4
Business overview .....	5
Group financial review for the second quarter of 2024 .....	5
Group financial review for the first half of 2024 .....	6
Corporate events .....	7
Environmental, Social and Governance (ESG) .....	7
Risks and uncertainties .....	7
Related parties .....	8
Subsequent events .....	8
Outlook .....	8
Forward looking statements .....	9
Responsibility statement .....	10
Condensed consolidated statement of comprehensive income .....	11
Condensed consolidated statement of financial position .....	12
Condensed consolidated statement of cash flows .....	14
Condensed consolidated statement of changes in equity .....	15
Notes to the condensed consolidated interim financial statements .....	16
Definitions of Alternative Performance Measures (APM) .....	21

## Highlights for the first half year 2024

- In the first half of 2024, Navamedic's revenue grew by 12.8 per cent YoY and amounted to NOK 277.2 million
- EBITDA amounted to NOK 41.1 million (adjusted EBITDA\* NOK 26.3 million in 2023)
- The Company's gross margin was high at 42.9 per cent, which included a milestone payment from the Flexilev out-licensing agreement with Orion Pharma (LY was 40.9 per cent)
- Navamedic signed a licence and supply agreement with Orion Corporation for Flexilev®, including the OraFID® dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Through the signed agreement, Orion has been granted the exclusive right to market, distribute, and sell Flexilev® in 27 countries in Europe, including the "big five": Germany, France, Italy, Spain and the UK
- In May, Navamedic renewed its contract with The Norwegian Hospital Procurement Trust to continue delivering antibiotics to Norwegian hospitals. The renewed contract is expected to contribute more than 20 per cent growth to the total antibiotic portfolio revenues
- Following the launch of Eroxon® in Norway in February, Navamedic launched the product in Sweden in May

## Key figures

<i>(in NOK '1000)</i>	Q2 2024	Q2 2023	YTD 2024	YTD 2023	2023
Total revenue	156 305	123 967	277 178	245 686	511 997
Gross profit *	72 109	50 134	118 923	100 382	199 054
Adjusted EBITDA (less transaction costs) *	32 678	10 501	41 136	26 288	51 566
EBITDA *	32 678	-1 834	41 136	13 953	35 505
Operating profit (EBIT) *	28 917	-4 038	33 814	9 916	23 580
Profit before tax	24 846	-17 076	24 044	491	10 834
Net profit / loss (-)	20 311	-15 774	18 728	-2 607	3 305
Total assets	547 391	455 247	547 391	455 247	524 304
Total equity	244 102	211 444	244 102	211 444	222 391
Gross margin (%) *	46.1 %	40.4 %	42.9 %	40.9 %	38.9 %
EBITDA margin (%) *	20.9 %	-1.5 %	14.8 %	5.7 %	6.9 %
Equity ratio (%) *	44.6 %	46.4 %	44.6 %	46.4 %	42.4 %

\* Alternative performance measures (APMs)

## Comment from the CEO

Halfway into 2024, Navamedic can look back at an exciting first six months. There has been a lot of activity across the business, which has broadened Navamedic's geographical reach and product portfolio. Having been early to identify treatment areas with significant medical need and consumer demand, such as infections requiring antibiotics in hospitals and the obesity epidemic, we have seen good growth across our key business areas: RX, Consumer and Hospital.



**Kathrine Gamborg Andreassen**  
Chief Executive Officer

We started the year by launching Eroxon<sup>®</sup>, a breakthrough treatment for erectile dysfunction in men, in Norway in February. Within two weeks, the product was labelled a bestseller by an online pharmacy, and since its launch, it has been a high performing product as part of Navamedic's Consumer Health segment. With the aim of launching this product across all of the Nordic countries, Eroxon<sup>®</sup> was introduced to the Swedish market in May. Before the end of 2024, we will launch Eroxon<sup>®</sup> in Finland and have plans to launch the product in Denmark during the spring of 2025. The successful launch of Eroxon<sup>®</sup> is a testament to the efficiency of our marketing and distribution channels.

In May, we also announced that Navamedic had renewed and extended its contract with The Norwegian Hospital Procurement Trust until 2027. This contract is important, as it means we will continue to deliver critical antibiotics to Norwegian hospitals. We are proud to again have been selected as a provider of these much needed antibiotics and expect the contract to contribute significantly to our revenues for the antibiotics portfolio.

We have taken significant steps to increase patient access to Flexilev<sup>®</sup> and OraFID<sup>®</sup>, a novel prescription treatment for Parkinson's disease (PD) and unique dispenser. In June, we signed a License & Supply Agreement with Orion Corporation, which has been granted exclusive rights to market, distribute and sell Flexilev<sup>®</sup> across 27 European countries, including the "big five": Germany, France, Italy, Spain and the UK. Navamedic will remain responsible for Norway, Sweden, Denmark and Iceland. PD is a chronic and progressive disease whereby patients are met with few treatment options. To Navamedic, this agreement represents a significant opportunity for patients to access one of the few treatment options available on the market. We have high ambitions for this much-needed treatment, which has already proven itself to be a top-performing product. We are confident that the partnership with Orion Corporation will contribute substantially to the continued growth of Flexilev<sup>®</sup> and OraFID<sup>®</sup> in Europe.

As part of the ongoing commercialisation strategy for the product, we are working to gain regulatory approval for Flexilev<sup>®</sup> in the new OraFID<sup>®</sup> dispenser. As an initial priority, Navamedic will apply for marketing authorization in ten European countries and plan to launch the product across the Nordics in the second quarter of 2025.

A key driver for everyone at Navamedic is to be a proud contributor to public health, which includes identifying treatments and products that can enhance people's quality of life and ensuring that they are accessible, either through hospitals or pharmacies.

In the first half of the year, we also had the opportunity to welcome new shareholders as Ingerø Reiten Investment Company (IRIC) sold its 17 percent interest in Navamedic. Alongside new shareholders, we also welcomed Jostein Davidsen as Chair of the board of directors. Moving ahead, we look forward to working closely with the board to reach our mid-term ambition of becoming a NOK 1 billion revenue company. With a solid foundation and continued operational progress, we are well on our way to achieving this goal.

## Business overview

Navamedic ASA is a Nordic pharma company listed on the Oslo Stock Exchange. The Company is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers.

Navamedic is present in all the Nordic countries and Benelux. The company's vision is to become a leading pharmaceutical company by providing access to high-quality products for patients and delivering sustainable growth both organically and through acquisitions. With the recent acquisition of the Flexilev/Orafid, Navamedic has expanded its strategic vision to also include making its Parkinson product offering available on a global basis throughout-licensing with partnerships.

Navamedic's strategy is to maximize the potential of its existing products, entering into new distribution and in-licensing agreements, out-license the products and by making bolt-on acquisitions of products, brands and portfolios.

In the first half of 2024, revenues amounted to NOK 277.2 million, up from NOK 245.7 million in the same period last year, while the gross margin was 42.9%, compared to 40.9% in the first half of 2023. EBITDA ended at NOK 41.1 million in the first half of 2024, compared to adjusted EBITDA of NOK 26.3 million in 2023.

In the period, Navamedic signed a license and supply agreement with Orion Corporation for Flexilev<sup>®</sup>, including the OraFID<sup>®</sup> dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product.

## Group financial review for the second quarter of 2024

### Income statement

Revenues in the second quarter of 2024 were NOK 156.3 million, an increase of 26.2% from NOK 124.0 million in the second quarter last year. The increase is driven by milestone fee from Orion corporation of NOK 22.7 million as well as organic growth across all of Navamedic's business areas (Hospital, Rx and Consumer Health). Adjusted for milestone fee income, the gross margin was 37.0% in the second quarter of 2024 compared to 40.4% in 2023 due to product mix and currency effects. EBITDA for the quarter was NOK 32.7 million, compared to adjusted EBITDA of NOK 10.5 million in the corresponding quarter last year.

The operating result (EBIT) for the second quarter was NOK 28.9 million, compared to negative NOK 4.0 million in the second quarter of 2023. Net financials were negative NOK 4.1 million in the second quarter of 2024, compared to negative NOK 13.0 million in the corresponding quarter last year.

Profit before tax was NOK 24.8 million in the second quarter 2024, compared to negative NOK 17.1 million in the second quarter of 2023.

## Cash flow

The Group's cash flow from operating activities was NOK 11.1 million in the second quarter of 2024 driven by operating profits coupled with changes in working capital.

The Group's cash flow from investing activities was negative NOK 0.2 million while cash flow from financing activities of negative NOK 13.1 million was driven by the repayment of loans and interest.

# Group financial review for the first half of 2024

## Income statement

For the first half of 2024, the Group revenues were NOK 277.2 million, up from NOK 245.7 million in the first half of 2023, representing an increase of 12.8%. The growth is mostly the result of growth in our Antibiotics product portfolio, Imdur, the launch of Eroxon as well as the revenues from the Orion milestone fee.

EBITDA in the first half of 2023 was NOK 41.1 million, compared to adjusted EBITDA of NOK 26.3 million in the corresponding period last year.

The operating result (EBIT) for the first half of 2024 was NOK 33.8 million, compared to NOK 9.9 million in the same period last year. Net financials were negative NOK 9.8 million in the first half of 2024, compared to negative NOK 9.4 million in the same period last year. Profit before tax was NOK 24.0 million in the first half of 2024, up from NOK 0.5 million in the corresponding period last year.

Net profit was NOK 18.7 million in the first half of 2024, compared to net loss of NOK 2.6 million in the same period last year.

## Financial position

The Group's consolidated total assets were NOK 547.4 million at 30 June 2024, up from NOK 524.3 million at year-end 2023, of which non-current assets were NOK 258.0 million. Current assets increased to NOK 289.4 million from NOK 210.1 million at 31 December 2023. The increase in total assets is primarily driven by increase in accounts receivable due to the receivable for the milestone fee from Orion Corporation. On the asset side of the balance sheet at 30 June 2024, Navamedic has the loan to Observe Medical ASA in the amount of NOK 51.4 million. Observe Medical ASA has communicated to the market that the company is working on securing financing. As at 30 June, 2024, Navamedic assesses that the recoverable amount of the loan is equal to the carrying amount in the balance sheet. Navamedic is continuously monitoring the development in the Observe Medical ASA.

Non-current liabilities are NOK 102.8 million per 30 June 2024, a decrease from NOK 112.6 million at 31 December 2023, primarily due to repayment of loans and borrowings. At the end of the first half 2024, Navamedic had an equity of NOK 244.1 million, compared to NOK 222.4 million per 31 December 2023, representing an equity ratio of 45%.

The Group had current liabilities of NOK 200.5 million compared to NOK 189.3 million at 31 December 2023. The increase is mainly related to increase in account payables and other current liabilities.

### Cash flow

The Group had a net cash flow from operating activities in the first half of 2024 of NOK 5.5 million, (NOK 2.1 million in 2023), including negative effects from the changes in working capital due to receivables from Orion milestone fee. Net cash from investing activities ended at negative NOK 0.4 million in the first half of 2024, compared to negative NOK 89.2 million in the same period last year, as Navamedic completed the purchase of the shares in Sensidose AB in 2023. The net cash flow from financing activities was negative NOK 15.0 million in the first half of 2024, compared to NOK 65.8 million in the corresponding period last year. The cash and cash equivalents were NOK 28.3 million at 30 June 2024.

### Corporate events

At the Annual General Meeting, a new Chairman of the Board was elected, as well as two Board members which were replaced. There were no other significant corporate events that warrant further disclosure during the first half of 2024.

### Sustainability and Environmental, Social and Governance (ESG)

Navamedic made significant progress in its sustainability efforts in 2023 which continued in 2024. We are committed to deliver on our strategy for sustainable business outlined in our Sustainability report for 2023, available at our company website, where we provide important information about initiatives, efforts and strategies we implement in the environmental, social and governance area as well as information about our Co2 emission and measures for reduction. In addition, Navamedic publishes a due diligence report about human rights and decent work conditions.

### Risks and uncertainties

Navamedic is a pharmaceutical company providing high-quality products to hospitals and pharmacies. The operational and financial risks Navamedic is exposed to differ little from what would be considered normal risks as a distributor of pharmaceuticals. The Company is not directly exposed to the risk of the development and production of the products it sells.

In general, the Group's operation exposes it to both operational risk, financial risks and other risks. Operations risk factors include increased competition, out-of-stock situations and/or disruption in the supply chain and price reductions. Financial risks include currency risk, interest rate risk, credit risk, liquidity risk and long-term financing and exchange rate fluctuations. Note that the above is not an exhaustive list of risks and uncertainties the company may be exposed to.

## Related parties

Navamedic sells a significant amount of Imdur from its partner Top Ridge Pharma. As at the end of Q2, Top Ridge owns 917 522 shares in Navamedic. The terms in the agreements between the parties are based on arm's length principles. InfoRLife SA/ACS Dobfar is also a significant partner and supplier of products to Navamedic. At the end of Q2, InfoRLife SA owned 1 053 775 shares in Navamedic.

## Subsequent events

Subsequent to the reporting period ended on 30 June 2024, no events have been identified that require disclosure.

## Outlook

Navamedic has the goal of becoming a leading pharmaceutical company in the Nordics, with footprint in Northern Europe. Growth shall be achieved by developing the existing product portfolio, licensing new products and through acquisitions.

We see significant potential to add more products in the existing distribution platform in the Nordic region, the Baltic states and the Benelux countries. With a well-functioning system of logistics and distribution, as well as skilled salespeople who regularly meet with hospitals, specialists, general practitioners and pharmacies, we have the strength to launch new prescription and non-prescription pharmaceuticals in our markets.

The company will also actively work to build and retain value through ownership and further development of assets, both short- and long-term. Through licensing rights and developing and purchasing products, the company will increase its share of pharmaceuticals that we ourselves own the marketing rights and trademarks to. The company has solid expertise and capacity within this field and is in the process of building up its portfolio of potential products to be launched in the coming years.

Further to the above, the acquisitions of Impolin AB in 2022 and Sensidose AB in 2023 have expanded and solidified the Navamedic platform, enabling the company to out-license its products both in Europe and globally. Given that agreement with Orion Pharma to out-license Flexilev with Orafid in Europe, the groundwork is laid and further opportunities for both geographical expansion as well as out-licensing the other products Navamedic owns (Medmade and Absolut Torr) will be sought.

As an integral part of the Navamedic strategy, we will also continue to seek accretive acquisition opportunities with the right strategic fit.

Based on the strategy and outlook, the board of Navamedic expects that the company will continue the positive development in the second half of 2024. The company reiterates its ambition of building a NOK 1 billion revenue company mid-term, including M&A.



## Forward looking statements

This report contains statements regarding the future in connection with the Group's growth initiatives, profit figures, outlook, strategies and objectives. In particular, the section "Outlook" contains forward-looking statements regarding the Group's expectations. All statements regarding the future are subject to inherent risks and uncertainties, and many factors can lead to actual results and developments deviating substantially from what has been expressed or implied in such statements. These factors include the risk factors relating to the Group's activities described in Navamedic ASA's 2023 Annual Report.

## Responsibility statement

We confirm to the best of our knowledge that the condensed consolidated financial statements for the period 1 January to 30 June 2024 have been prepared in accordance with IAS 34 'Interim Financial Reporting' as approved by the EU and gives a true and fair view of the Group's assets, liabilities, financial position and profit and loss as a whole. We also confirm, to the best of our knowledge, that the interim report includes a fair review of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements and a description of the principal risks and uncertainties for the remaining six months of the financial year, and major related party transactions.

The Board of Directors and CEO of Navamedic ASA

Oslo, 15 August 2024




**Jostein Davidsen (sign.)**  
Chairman



**Edmée Steenken (sign.)**  
Board member



**Annika Kollén (sign.)**  
Board member



**Kjell-Erik Nordby (sign.)**  
Board member



**Rune Wahl (sign.)**  
Board member



**Åsa Kornfeld (sign.)**  
Board member



**Kathrine Gamborg Andreassen (sign.)**  
CEO

## Condensed consolidated statement of comprehensive income

<i>(in NOK '1000)</i>	<b>Q2 2024</b>	<b>Q2 2023</b>	<b>YTD 2024</b>	<b>YTD 2023</b>	<b>Year 2023</b>
Operating revenue	156 305	123 967	277 178	245 686	511 997
<b>Total revenue</b>	<b>156 305</b>	<b>123 967</b>	<b>277 178</b>	<b>245 686</b>	<b>511 997</b>
Cost of materials	-84 196	-73 834	-158 255	-145 305	-312 944
<b>Gross profit</b>	<b>72 109</b>	<b>50 134</b>	<b>118 923</b>	<b>100 382</b>	<b>199 054</b>
<i>Gross profit %</i>	46.1 %	40.4 %	42.9 %	40.9 %	38.9 %
Payroll expense	-16 386	-13 539	-32 787	-29 563	-63 673
Other operating cost excluding transactions cost	-23 046	-26 094	-45 000	-44 530	-83 815
<b>Adjusted EBITDA (excluding transaction cost)</b>	<b>32 678</b>	<b>10 501</b>	<b>41 136</b>	<b>26 288</b>	<b>51 566</b>
<i>Adjusted EBITDA %</i>	20.9 %	8.5 %	14.8 %	10.7 %	10.1 %
Transaction cost	0	-12 335	0	-12 335	-16 061
<b>EBITDA</b>	<b>32 678</b>	<b>-1 834</b>	<b>41 136</b>	<b>13 953</b>	<b>35 505</b>
<i>EBITDA %</i>	20.9 %	-1.5 %	14.8 %	5.7 %	6.9 %
Depreciation	-1 083	-1 009	-2 011	-1 654	-3 315
Amortization	-2 678	-1 195	-5 312	-2 383	-8 610
<b>Operating result (EBIT)</b>	<b>28 917</b>	<b>-4 038</b>	<b>33 814</b>	<b>9 916</b>	<b>23 580</b>
Financial income	1 233	953	2 382	1 789	4 351
Financial expenses	-4 857	-4 826	-8 876	-6 475	-14 337
Net currency gain/losses	- 535	-7 607	-3 745	598	5 939
Net change in fair value current financial assets	89	-1 558	469	-5 338	-8 699
<b>Net financial income and expenses</b>	<b>-4 070</b>	<b>-13 038</b>	<b>-9 770</b>	<b>-9 426</b>	<b>-12 746</b>
<b>Profit before tax</b>	<b>24 846</b>	<b>-17 076</b>	<b>24 044</b>	<b>491</b>	<b>10 834</b>
Income taxes	-4 536	1 301	-5 316	-3 098	-7 529
<b>Net profit / loss (-)</b>	<b>20 311</b>	<b>-15 774</b>	<b>18 728</b>	<b>-2 607</b>	<b>3 305</b>
<i>Other comprehensive income that may be reclassified subsequently to profit or loss</i>					
Currency translation differences	-3 388	-1 036	- 970	6	502
<b>Total comprehensive income for the period</b>	<b>16 923</b>	<b>-16 810</b>	<b>17 759</b>	<b>-2 601</b>	<b>3 807</b>
Earnings per share basic (NOK)	1.165	-0.916	1.077	-0.151	0.191
Earnings per share diluted (NOK)	1.146	-0.897	1.064	-0.149	0.188

## Condensed consolidated statement of financial position

(in NOK '1000)

	30.06.2024	30.06.2023	31.12.2023
<b>Assets</b>			
<b>Non-current assets</b>			
<b>Intangible non-current assets</b>			
Goodwill	155 347	142 839	156 729
Deferred tax assets	930	835	930
Other intangible assets	92 316	83 732	97 627
<b>Total intangible non-current assets</b>	<b>248 593</b>	<b>227 406</b>	<b>255 286</b>
<b>Other non-current assets</b>			
Property, plant & equipment	3 497	1 735	3 692
Right of use assets	5 884	6 679	6 060
Non-current loans receivable	0	0	49 149
<b>Total other non-current assets</b>	<b>9 381</b>	<b>8 414</b>	<b>58 900</b>
<b>Total non-current assets</b>	<b>257 975</b>	<b>235 820</b>	<b>314 186</b>
<b>Current assets</b>			
Tax receivables	12 927	14 947	14 858
Inventories	113 897	67 229	105 200
Trade and other receivables	80 978	55 674	50 631
Current loans receivable	51 432	42 239	0
Cash and cash equivalents	28 320	33 303	38 036
Other current financial assets	1 862	6 035	1 393
<b>Total current assets</b>	<b>289 416</b>	<b>219 427</b>	<b>210 118</b>
<b>Total assets</b>	<b>547 391</b>	<b>455 247</b>	<b>524 304</b>

(in NOK '1000)

30.06.2024    30.06.2023    31.12.2023

**Equity**
***Paid in equity***

Share capital	12 900	12 749	12 841
Share premium reserve	194 038	190 408	192 577
<b>Total paid in equity</b>	<b>206 938</b>	<b>203 157</b>	<b>205 418</b>

***Retained earnings***

Retained earnings	37 164	8 287	16 973
<b>Total retained earnings</b>	<b>37 164</b>	<b>8 287</b>	<b>16 973</b>

<b>Total equity</b>	<b>244 102</b>	<b>211 444</b>	<b>222 391</b>
---------------------	----------------	----------------	----------------

**Liabilities**
***Non-current liabilities***

Non-current interest-bearing borrowings	87 078	103 647	95 479
Non-current license liabilities	4 105	3 781	3 988
Non-current right of use liabilities	2 914	4 676	3 892
Deferred tax liabilities	8 666	0	9 271
<b>Total non-current liabilities</b>	<b>102 763</b>	<b>112 104</b>	<b>112 629</b>

***Current liabilities***

Current interest-bearing borrowings	49 208	23 259	51 067
Trade and other payables	73 445	49 673	68 300
Current right of use liabilities	3 284	2 230	2 453
Current license liabilities	16 699	231	16 861
Taxes payable	10 632	3 327	8 149
Other current liabilities	47 257	52 980	42 454
<b>Total current liabilities</b>	<b>200 525</b>	<b>131 699</b>	<b>189 284</b>

<b>Total liabilities</b>	<b>303 288</b>	<b>243 803</b>	<b>301 913</b>
--------------------------	----------------	----------------	----------------

<b>Total equity and liabilities</b>	<b>547 391</b>	<b>455 247</b>	<b>524 304</b>
-------------------------------------	----------------	----------------	----------------

## Condensed consolidated statement of cash flows

(in NOK '1000)

	Q2 2024	Q2 2023	YTD 2024	YTD 2023	Year 2023
<b>Cash flow from operating activities</b>					
Profit before tax continuing operations	24 846	-17 113	24 044	491	10 834
Taxes paid	-92	5	-2 856	-4 801	-5 129
Depreciation, amortization and impairment	3 761	2 204	7 322	4 037	11 926
Financial and other income / expenses without cash flow effect	727	12 661	7 319	13 705	12 783
Payment of license liabilities	0	0	0	0	-120
Changes in inventory	6 311	15 994	-9 888	14 217	-23 754
Changes in trade and other receivables	-22 796	-7 330	-30 348	-10 028	-4 985
Changes in trade and other payables	-6 190	-462	5 145	-17 861	765
Changes in other current items	4 537	-6 944	4 803	2 353	-140
<b>Net cash flow from operating activities</b>	<b>11 104</b>	<b>-987</b>	<b>5 541</b>	<b>2 112</b>	<b>2 179</b>
<b>Cash flow from investing activities</b>					
Acquisition of tangible and intangible assets	-247	0	-439	-165	-2 198
Loans granted	0	0	0	0	-5 000
Interest received	60	73	67	150	614
Purchase of shares in other companies net of cash acquired	0	-89 182	0	-89 182	-97 999
<b>Net cash flow from investing activities</b>	<b>-187</b>	<b>-89 109</b>	<b>-372</b>	<b>-89 197</b>	<b>-104 583</b>
<b>Cash flow from financing activities</b>					
Loans received	0	124 828	0	124 828	145 110
Payment of loans	-9 883	-52 752	-9 883	-55 265	-54 268
Interest paid	-2 371	-1 713	-5 108	-2 504	-7 228
Share issues	0	0	1 520	0	2 262
Payment of lease liabilities	-827	-633	-1 523	-1 215	-2 641
<b>Net cash flow from financing activities</b>	<b>-13 081</b>	<b>69 730</b>	<b>-14 994</b>	<b>65 844</b>	<b>83 235</b>
Changes in currency	1 390	-3 061	109	-752	1 909
<b>Net change in cash</b>	<b>-775</b>	<b>-23 427</b>	<b>-9 716</b>	<b>-21 993</b>	<b>-17 260</b>
Cash and cash equivalents start period	29 095	56 729	38 036	55 296	55 296
<b>Cash and cash equivalents end period</b>	<b>28 320</b>	<b>33 303</b>	<b>28 320</b>	<b>33 303</b>	<b>38 036</b>

## Condensed consolidated statement of changes in equity

<i>(in NOK '1000)</i>	Share capital	Share premium reserve	Retained earnings	Total
<b>Balance as at 1 January 2023</b>	<b>12 749</b>	<b>190 408</b>	<b>6 563</b>	<b>209 720</b>
Net profit / loss (-)			3 305	3 305
Currency translations differences			502	502
Capital increase	93	2 169		2 262
Share options			6 603	6 603
<b>Balance as at 31 December 2023</b>	<b>12 841</b>	<b>192 577</b>	<b>16 973</b>	<b>222 391</b>
<b>Balance as at 1 January 2024</b>	<b>12 841</b>	<b>192 577</b>	<b>16 973</b>	<b>222 391</b>
Net profit / loss (-)			18 728	18 728
Currency translation differences			- 970	- 970
Share capital increase	59	1 461		1 520
Share options			2 432	2 432
<b>Balance as at 30 June 2024</b>	<b>12 900</b>	<b>194 038</b>	<b>37 164</b>	<b>244 102</b>

<i>(in NOK '1000)</i>	Share capital	Share premium	Retained	Total
<b>Balance as at 1 January 2023</b>	<b>12 749</b>	<b>190 408</b>	<b>6 563</b>	<b>209 720</b>
Net profit / loss (-)			-2 607	-2 607
Currency translation differences			6	6
Share options			4 324	4 324
<b>Balance as at 30 June 2023</b>	<b>12 749</b>	<b>190 408</b>	<b>8 287</b>	<b>211 444</b>

# Notes to the condensed consolidated interim financial statements

## 1. General information

Navamedic ASA is a public limited liability company domiciled in Norway. The business of the Group is associated with distribution, marketing and sales of pharmaceutical products and related technical medical equipment. The Company's shares are listed on the Oslo Stock Exchange under the ticker NAVA. The Company's registered office is Henrik Ibsens gate 100, 0255 Oslo, Norway. Navamedic Group comprises Navamedic ASA and the 100% owned subsidiaries Navamedic AB (Sweden), Navamedic AS (Norway) and Sensidose AB (Sweden).

## 2. Nature of operation

Navamedic ASA is a Nordic pharma company with footprint in Northern Europe listed on the Oslo Stock Exchange. The company is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. The product portfolio consists of prescription and non-prescription pharmaceuticals as well as other healthcare products registered as medical nutrition and medical devices. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like Greece. Through its subsidiaries Navamedic AB, Navamedic AS and Sensidose AB, the Group distributes more than 40 brands of products from 20 international producers and brand owners in the European market. Navamedic's ambition is to grow by expanding its product portfolio and launching existing products in new markets.

## 3. Basis of preparation

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the EU. The condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements for the year ended 31 December 2023 (the Annual Financial Statements), as they provide an update of previously reported information. The accounting policies used are consistent with those used in the Annual Financial Statements.

The condensed consolidated interim financial statements have not been audited. Navamedic's Board of Directors and CEO approved these condensed consolidated interim financial statements on 15 August 2024.

Navamedic ASA's functional currency and the presentation currency for the financial statements is NOK. In the absence of any statement to the contrary, all financial information is reported in NOK thousands. As a result of rounding adjustments, the figures in the financial statements and notes may not add up to the totals.



#### 4. Critical accounting estimates and discretionary assessments

Estimates and discretionary assessments are evaluated on an ongoing basis and are based on past experiences and other factors, including expectations concerning future events regarded as probable under current circumstances. The Group prepares estimates and makes assumptions about the future. The accounting estimates that follow from these will, by definition, seldom be fully in line with the final outcomes. In preparing these interim condensed consolidated financial statements, the estimates and assumptions that represent a risk of material changes to the carrying values for assets and liabilities during the next accounting year are the same as those applied to the annual consolidated financial statements for 2023.

#### 5. Change in accounting policies

The Group has not implemented any changes in accounting policies for the first half year of 2024. The same accounting policies are applied for the interim report as are applied in the annual financial statements.

#### 6. Earnings per share

Earnings per share (EPS) are calculated on the basis of net profit (loss) (result allocated to shareholders of the company). This result is divided by a weighted average number of outstanding shares over the periods, reduced by treasury shares (none for the periods presented). Dilutive EPS are the same as ordinary EPS for all periods presented in the table below.

<i>(in NOK '1000)</i>	<b>Q2 2024</b>	<b>Q2 2023</b>	<b>YTD 2024</b>	<b>YTD 2023</b>	<b>2023</b>
Net profit / loss (-)	20 311	-15 774	18 728	-2 607	3 305
Weighted average shares issued	17 431 898	17 227 777	17 392 556	17 227 777	17 274 352
Dilutive potential ordinary shares	286 079	359 674	215 372	327 190	338 536
Basic earnings per share	1.1651	-0.9156	1.0768	-0.1513	0.1913
Diluted earnings per share	1.1463	-0.8969	1.0636	-0.1485	0.1876

#### 7. Segment information

Navamedic has only one segment, the Pharma and Healthcare segment. The reporting structure reflects the company's business and product composition.

The Pharma and Healthcare segment consists of pharmaceuticals and medical nutrition products that Navamedic markets, sells and distributes to hospitals, pharmacies and patients, bought from product suppliers and manufacturers in Europe and other countries.

In the first quarter of 2023, Navamedic implemented a new classification of its products, divided into three product categories:

- **The RX area** comprises Navamedic's prescription products and categories, including obesity, urology, neurology, and cardiology products such as Mysimba<sup>®</sup> (prescription pharmaceutical for treatment of obesity), Elmiron<sup>®</sup>/Gepan<sup>®</sup> (products for the treatment of painful bladder syndrome), Flexilev (microtablets for the treatment of Parkinson's disease) and cardiology products such as Imdur<sup>®</sup> (used to prevent angina pectoris) and Nitrolingual (acute relief of angina pectoris)
- **The Consumer Health area** comprises Navamedic's over-the-counter products, available to patients without a prescription in the pharmacies or drugstore (NL only), the area includes obesity (Modifast – products for meal replacement), gastro (brands such as Alflorex, SmectaGo and Forlax), pain (ThermaCare), cough&cold and intimate health (Eroxon).
- **Hospital**, products included in tenders such as a broad portfolio of niched medical nutrition products for rare diseases such as Phenylketonuria, and intravenous antibiotics for hospital use.

## 8. Share options

Key management personnel in Navamedic ASA receive parts of their salary as share-based remuneration.

### Reconciliation outstanding options

	Number of instruments	Weighted average strike price
<b>Outstanding options 1 January 2023</b>	<b>510 000</b>	<b>18.78</b>
Exercised	-25 000	14.46
Exercised	-100 000	19.00
Granted	1400 000	33.00
<b>Total outstanding options 31 December 2023</b>	<b>1 785 000</b>	<b>29.98</b>
<b>Outstanding options 1 January 2024</b>	<b>1 785 000</b>	<b>29.98</b>
Exercised	-80 000	19.00
<b>Total outstanding options 30 June 2023</b>	<b>1 705 000</b>	<b>30.50</b>

### Outstanding options 31 December 2023

	Number of options	Of which vested	Weighted Average remaining contractual life (years)
Strike price 19,00	385 000	385 000	0.50
Strike price 33,00	1400 000	0	1.46
<b>Total outstanding options 31 December 2023</b>	<b>1 785 000</b>	<b>340 000</b>	

### Outstanding options 30 June 2024

	Number of options	Of which vested	Weighted Average remaining contractual life (years)
Strike price 19,00	305 000	305 000	0.00
Strike price 33,00	1 400 000	466 667	1.67
<b>Total outstanding options 30 June 2024</b>	<b>1 705 000</b>	<b>771 667</b>	

All the options granted in 2023 vest 1/3 every 12 months after the grant date (if the option holder is still employed). Options that have not been exercised will lapse 4 years after the grant date.

Shares received from exercised options are subject to a lock-up period of 12 months. The lock-up obligations shall not prevent the option holders from selling the amount of the option shares necessary to finance the exercise price, as well as the tax payable as a consequence of the exercise of options.

## 9. Significant events subsequent to the end of the reporting period

After the reporting period ended on 30 June 2023 and up to the date these condensed consolidated financial statements have been approved for issue, no events have been identified that require disclosure.

The Board of Directors and CEO of Navamedic ASA

Oslo, 15 August 2024




**Jostein Davidsen (sign.)**  
Chairman



**Edmée Steenken (sign.)**  
Board member



**Annika Kollén (sign.)**  
Board member



**Kjell-Erik Nordby (sign.)**  
Board member



**Rune Wahl (sign.)**  
Board member



**Åsa Kornfeld (sign.)**  
Board member



**Kathrine Gamborg Andreassen**  
**(sign.)**  
CEO

## Definitions of Alternative Performance Measures (APM)

Navamedic's financial information is prepared in accordance with international financial reporting standards as adopted by the EU (IFRS). In addition, the company presents alternative performance measures (APMs). The APMs are regularly reviewed by management and their aim is to enhance stakeholders' understanding of the company's performance. APMs presented may be determined or calculated differently by other companies.

APMs:

- **EBITDA** is equal to earnings before interest, tax, depreciation and amortization. EBITDA is a sub-total in the consolidated statement of comprehensive income.
- **EBITDA margin** is equal to EBITDA as a percentage of total operating revenues.
- **Adjusted EBITDA** is EBITDA (as defined above) excluding acquisition related cost ("transaction cost").
- **Gross profit** is equal to total revenues minus cost of materials. Gross profit is a sub-total in the condensed consolidated income statement.
- **Gross margin** is equal to gross profit as a percentage of total operating revenues.
- **Equity ratio** is equal to total equity as a percentage of total shareholders' equity and liabilities.



**Navamedic ASA**

Henrik Ibsensgate 100  
0255 Oslo

Telephone: +47 67 11 25 40  
E-mail: [firma@navamedic.com](mailto:firma@navamedic.com)  
[www.navamedic.com](http://www.navamedic.com)